Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Endometriosis, Breast Cancer, Pancreas Cancer
- Main trialPhase 2
- “This is a Phase IIa, open-label, non-randomised and non-placebo-controlled study. The study is designed to evaluate the diagnostic value and safety of a single intravenous dose of SN132D in up to 18 participants with suspected endometriosis. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.”In the company’s words, NCT05664828 on ClinicalTrials.gov
- Other names
- SpagoPix
Other drugs for Endometriosis
- ElagolixAbbVie · Phase 3
- LinzagolixKissei Pharmaceutical Co., Ltd. · Phase 3
- HMI-115Hope Medicine (Nanjing) Co., Ltd · Phase 3
- RelugolixSumitomo Pharma America, Inc. · Phase 3
- VipoglanstatGesynta Pharma AB · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 20 Jun 2023 | Efficacy of SN132D in Patients With Suspected Endometriosis | |
| Phase 1Completed | 30 Nov 2022 | A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026